Investigational drug · Phase 3
HS-20137
Also called: QX004N
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate-to-severe Plaque Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "HS-20137"
First trial start
2025
Jun 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20137", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate-to-severe Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20137" as an intervention, largest first.
- A Study of HS-20137 in Participants with Moderate-to-severe Plaque PsoriasisPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06844799 · 720 participants (planned) · Start Jun 10, 2025 · Primary completion Mar 31, 2027
Drug: HS-20137; Placebo&HS-20137 · For: Moderate-to-severe Plaque Psoriasis
Hansoh BioMedical R&D CompanyIndustry
NCT07879885 · 390 participants (planned) · Start Jul 31, 2025 · Primary completion Mar 1, 2027
Drug: HS-20137 · For: Moderate-to-severe Plaque Psoriasis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.
Cai L, Wang X, Zhang L, et al. · Dermatol Ther (Heidelb) 2026
- Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial.
Li X, Li B, Yang D, et al. · JAMA Dermatol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.